iRhom2 Phosphorylation Depends on MAP Kinases Downstream of Toll-like Receptor Signaling
(A) Schematics illustrating how signaling downstream of TLR3/4, GPCRs, and PMA converges on MAPK activation. Inhibitors are highlighted in red. Adapted from Goldsmith and Dhanasekaran, 2007, Steinberg, 2008, and Oda and Kitano (2006).
(B) A combination of ERK- and p38-MAPK inhibitors prevent endogenous iRhom2 phosphorylation in LPS-stimulated BMDMs.
(C) MAPK inhibitors (MEK1/2, JNK, and p38) prevent endogenous iRhom2 phosphorylation in poly(I:C)-stimulated BMDM.
Throughout, cells were pre-treated for 30 min with inhibitors (2.5 μM PD184352 [MEK1/2 inhibitor], 5 μM SP600125 [JNK inhibitor], 1 μM SB 202190 [p38 inhibitor]) followed by LPS (15 min) or poly(I:C) (60 min) treatment.